Segment Information (Tables)

6 Months Ended

Jun. 30, 2024

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment for the three months ended June 30, 2024 and 2023 is as follows:

	Three Months Ended June 30, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Other				Total
Net revenues	$	-		$	1,278	$	10,833	$	-			$	12,111
Cost of revenues (excluding amortization of acquired intangible assets)		-			537		1,586		-				2,123
Direct expenses		3,422			447		5,784		10,054				19,707
Segment contribution	$	(3,422	)	$	294	$	3,463	$	(10,054	)		$	(9,719	)
Indirect expenses									456		(a)		456
Loss from operations												$	(10,175	)
(a) Components of other
Amortization									456
Total other								$	456

	Three Months Ended June 30, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	-		$	1,278	$	1,660		$	-			$	2,938
Cost of revenues (excluding amortization of acquired intangible assets)		-			485		317			-				802
Direct expenses		8,456			86		1,889			11,252				21,683
Segment contribution	$	(8,456	)	$	707	$	(546	)	$	(11,252	)		$	(19,547	)
Indirect expenses										22,929		(b)		22,929
Loss from operations													$	(42,476	)
(b) Components of other
Change in fair value of contingent consideration liability										(85,407	)
Change in fair value of contingent stock consideration										(10	)
IPR&D impairment										107,800
Amortization										546
Total other									$	22,929

Financial information by segment for the six months ended June 30, 2024 and 2023 is as follows:

	Six Months Ended June 30, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Other				Total
Net revenues	$	-		$	2,565	$	24,227	$	-			$	26,792
Cost of revenues (excluding amortization of acquired intangible assets)		-			714		3,049		-				3,763
Direct expenses		8,887			863		10,198		19,630				39,578
Segment contribution	$	(8,887	)	$	988	$	10,980	$	(19,630	)		$	(16,549	)
Indirect expenses									1,002		(a)		1,002
Loss from operations												$	(17,551	)
(a) Components of other
Amortization									1,002
Total other								$	1,002

	Six Months Ended June 30, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	-		$	2,635	$	4,238		$	-			$	6,873
Cost of revenues (excluding amortization of acquired intangible assets)		-			957		1,848			-				2,805
Direct expenses		48,618			430		4,898			22,407				76,353
Segment contribution	$	(48,618	)	$	1,248	$	(2,508	)	$	(22,407	)		$	(72,285	)
Indirect expenses										34,061		(b)		34,061
Loss from operations													$	(106,346	)
(b) Components of other
Change in fair value of contingent consideration liability										(104,339	)
Change in fair value of contingent stock consideration										(120	)
Goodwill impairment										29,633
IPR&D impairment										107,800
Amortization										1,087
Total other									$	34,061